A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Neuroblastoma Clinical Trial

Official title:

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02745756
• Other study ID #: MCC-17181
• Status: Withdrawn
• Phase: Phase 1
• First received: April 18, 2016
• Last updated: August 29, 2017
• Start date: April 14, 2016
• Est. completion date: August 21, 2017

Study information

• Verified date: August 2017
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study adds an experimental treatment with another type of cells, called dendritic cells. It is hoped that these cells may stimulate the immune system to react against neuroblastoma in much the same way that vaccines cause the immune system to react to certain viruses and bacteria. The physicians conducting this study have observed from previous research that neuroblastoma cells can be recognized by the immune system, and that they can be destroyed by immune cells.The main goal of this study is to see if giving participants this additional anti-Neuroblastoma vaccine reduces the risk of relapse following the Hematopoietic Stem Cell Transplant.

Description:

All patients who are enrolled in this study will receive all treatment at All Children's Hospital which is located at 501 6th Ave South, St. Petersburg, FL 33701. This includes autologous cell donation by apheresis, high dose cytotoxic therapy conditioning for autologous HPC transplant, post-transplant follow-up care, and all administration of dendritic cell vaccines and blood draws for post therapy immunological monitoring.

All preparation of cellular products, including hematopoietic progenitor cell products for autologous transplantation, and dendritic cell vaccine products, will be carried out in the Cell Therapy Facility located within the Moffitt Cancer Center, which is located at 12902 Magnolia Drive, Tampa, FL 33612.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 21, 2017
• Est. primary completion date: August 21, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Must have a histological diagnosis of neuroblastoma or ganglioneuroblastoma and be either newly diagnosed with high risk disease or have failed previous treatment: Patients who have failed previous treatment may have had no more than one earlier autologous HPC transplant.

• Participant is expected to undergo autologous HPC transplantation that is consistent with standard of care.

• Must have the presence of residual resectable disease for which surgery is clinically indicated, and will be performed at Johns Hopkins All Children's Hospital.

Exclusion Criteria:

• Not an eligible candidate for collection by apheresis or HPC transplant.

• History of autoimmune disorder or immune deficiency disorder.

Related Conditions & MeSH terms

• Neoplasms, Nerve Tissue
• Neuroblastoma

Intervention

Procedure:
• Autologous Hematopoietic Progenitor Cell Transplant
Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.

Biological:
• KLH and Tumor Lysate Pulsed DC Vaccine
Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute	Johns Hopkins All Children's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of Anti-tumor Effect	Whether a discernable anti-tumor effect resulting from autoHPCT therapy combined with dendritic cell vaccine therapy can be detected, either through monitoring of the patient's immune system for evidence of tumor specific immunity, or by monitoring for measureable clinical responses.	Up to 1 year
Primary	Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells	The feasibility of manufacturing both a hematopoietic progenitor cell graft and multiple tumor lysate pulsed dendritic cell vaccine treatments from the same starting apheresis product, culminating in delivery of the vaccines in the immediate period following myeloablative therapy and autologous hematopoietic progenitor cell transplant period (autoHPCT). For what fraction of eligible patients can sufficient tumor cell lysate and dendritic cells, necessary for the production of the dendritic cell vaccines, be obtained? From what fraction would it be possible to make additional vaccines?	Up to 1 year
Secondary	Occurrence of Dendritic Cell Related Adverse Events	Toxicities resulting from the administration of dendritic cell vaccines in the immediate post hematopoietic cell graft period.	Up to 1 year